TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact of the "Ten Steps for Healthy Feeding of Children Younger Than Two Years" in Health Centers
Brief Summary: A cluster randomized field trial to evaluate the impact that training healthcare workers in healthy feeding practices has on the nutrition and health of children.


Options:
A: Arm Label: I, Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary Advice | Arm Label: II, Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Dietary Advice; Assigned to Arm(s): I, Intervention
B: Arm Label: Umeå, vitamin D 25 microg/d, light skin; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D 25 microg/d | Arm Label: Umeå, vitamin D 10 microg/d, dark skin; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Vitamin D 10 microg/d | Arm Label: Umeå, vitamin D 10 microg/d, light skin; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Vitamin D 10 microg/d | Arm Label: Malmö, vitamin D 25 microg/d, dark skin; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D 25 microg/d | Arm Label: Malmö, vitamin D 25 microg/d, light skin; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D 25 microg/d | Arm Label: Malmö, vitamin D 10 microg/d, dark skin; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Vitamin D 10 microg/d | Arm Label: Malmö, vitamin D 10 microg/d, light skin; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Vitamin D 10 microg/d | Arm Label: Malmö, placebo, dark skin,; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: No extra vitamin D | Arm Label: Malmö, placebo, light skin; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: No extra vitamin D | Arm Label: Umeå, vitamin D 25 microg/d, dark skin; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D 25 microg/d | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D 25 microg/d; Assigned to Arm(s): Malmö, vitamin D 25 microg/d, dark skin, Malmö, vitamin D 25 microg/d, light skin, Umeå, vitamin D 25 microg/d, dark skin, Umeå, vitamin D 25 microg/d, light skin | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D 10 microg/d; Assigned to Arm(s): Malmö, vitamin D 10 microg/d, dark skin, Malmö, vitamin D 10 microg/d, light skin, Umeå, vitamin D 10 microg/d, dark skin, Umeå, vitamin D 10 microg/d, light skin | Intervention Type: DIETARY_SUPPLEMENT; Name: No extra vitamin D; Assigned to Arm(s): Malmö, placebo, dark skin,, Malmö, placebo, light skin
C: Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: intervention; Type: EXPERIMENTAL; Interventions: Other: Improving nutrition knowledge among mothers | Intervention Type: OTHER; Name: Improving nutrition knowledge among mothers; Assigned to Arm(s): intervention
D: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary Advice | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Dietary Advice; Assigned to Arm(s): Intervention

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact of the "Ten Steps for Healthy Feeding of Children Younger Than Two Years" in Health Centers
Brief Summary: A cluster randomized field trial to evaluate the impact that training healthcare workers in healthy feeding practices has on the nutrition and health of children.


Options:
A: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary Advice | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Dietary Advice; Assigned to Arm(s): Intervention
B: Arm Label: I, Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary Advice | Arm Label: II, Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Dietary Advice; Assigned to Arm(s): I, Intervention
C: Intervention Type: DRUG; Name: Fluoride varnish; Assigned to Arm(s): N/A
D: Arm Label: Loss-framed messages; Type: EXPERIMENTAL; Interventions: Behavioral: Framing (Loss-framed messages) | Arm Label: gain-framed messages; Type: EXPERIMENTAL; Interventions: Behavioral: Framing (Gain-framed messages) | Intervention Type: BEHAVIORAL; Name: Framing (Gain-framed messages); Assigned to Arm(s): gain-framed messages | Intervention Type: BEHAVIORAL; Name: Framing (Loss-framed messages); Assigned to Arm(s): Loss-framed messages

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Acceptability of the NuvaRing Among College and Graduate Students
Brief Summary: The ACCEPT study is a Phase IV trial in which women are randomized to either the NuvaRing® vaginal contraceptive ring or a low dose oral contraceptive to assess compliance, side effects, overall acceptability and intent to continue use of the method. The study is focused on the acceptability of the vaginal ring among female undergraduate or graduate students.


Options:
A: Arm Label: Contraceptive vaginal ring; Type: ACTIVE_COMPARATOR; Interventions: Device: NuvaRing | Arm Label: Oral contraceptive pill; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ortho Tri-cyclen Lo | Intervention Type: DRUG; Name: Ortho Tri-cyclen Lo; Assigned to Arm(s): Oral contraceptive pill | Intervention Type: DEVICE; Name: NuvaRing; Assigned to Arm(s): Contraceptive vaginal ring
B: Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Text Messages; Type: EXPERIMENTAL; Interventions: Other: Daily Text Messages | Intervention Type: OTHER; Name: Daily Text Messages; Assigned to Arm(s): Text Messages
C: Arm Label: Reproductive Life Planning (RLP); Type: EXPERIMENTAL; Interventions: Behavioral: Reproductive Life Planning (RLP), Behavioral: Contraception information | Arm Label: Reproductive Life Planning Plus (RLP+); Type: EXPERIMENTAL; Interventions: Behavioral: Reproductive Life Planning (RLP), Behavioral: Contraceptive Action Planning, Behavioral: Contraception information | Arm Label: Information-only control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Contraception information | Intervention Type: BEHAVIORAL; Name: Reproductive Life Planning (RLP); Assigned to Arm(s): Reproductive Life Planning (RLP), Reproductive Life Planning Plus (RLP+) | Intervention Type: BEHAVIORAL; Name: Contraceptive Action Planning; Assigned to Arm(s): Reproductive Life Planning Plus (RLP+) | Intervention Type: BEHAVIORAL; Name: Contraception information; Assigned to Arm(s): Information-only control, Reproductive Life Planning (RLP), Reproductive Life Planning Plus (RLP+)
D: Arm Label: Mobile phone-based intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Mobile phone-based intervention | Arm Label: Standard care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Mobile phone-based intervention; Assigned to Arm(s): Mobile phone-based intervention

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Acceptability of the NuvaRing Among College and Graduate Students
Brief Summary: The ACCEPT study is a Phase IV trial in which women are randomized to either the NuvaRing® vaginal contraceptive ring or a low dose oral contraceptive to assess compliance, side effects, overall acceptability and intent to continue use of the method. The study is focused on the acceptability of the vaginal ring among female undergraduate or graduate students.


Options:
A: Intervention Type: BEHAVIORAL; Name: Quick start oral contraceptive initiation; Assigned to Arm(s): N/A
B: Arm Label: Contraceptive vaginal ring; Type: ACTIVE_COMPARATOR; Interventions: Device: NuvaRing | Arm Label: Oral contraceptive pill; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ortho Tri-cyclen Lo | Intervention Type: DRUG; Name: Ortho Tri-cyclen Lo; Assigned to Arm(s): Oral contraceptive pill | Intervention Type: DEVICE; Name: NuvaRing; Assigned to Arm(s): Contraceptive vaginal ring
C: Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: ethinyl estradiol/norelgestromin transdermal contraceptive | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: ethinyl estradiol/etonogestrel vaginal ring | Intervention Type: DRUG; Name: ethinyl estradiol/etonogestrel vaginal ring; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: ethinyl estradiol/norelgestromin transdermal contraceptive; Assigned to Arm(s): 2
D: Arm Label: AG200-15 (cycles 1-13); Type: EXPERIMENTAL; Interventions: Drug: AG200-15 (cycles 1-13) | Arm Label: Lessina crossover to AG200-15; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lessina crossover to AG200-15 | Intervention Type: DRUG; Name: AG200-15 (cycles 1-13); Assigned to Arm(s): AG200-15 (cycles 1-13) | Intervention Type: DRUG; Name: Lessina crossover to AG200-15; Assigned to Arm(s): Lessina crossover to AG200-15

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Trauma-focused Cognitive-behavioural Therapy for Children: A Study of Process and Outcome.
Brief Summary: The purpose of this study is to determine whether Trauma focused cognitive behavioral therapy (TF-CBT)is more effective in the treatment of traumatized youth than treatment as usual(TAU).


Options:
A: Arm Label: Eye Movement Desensitization Reprocessing (EMDR); Type: EXPERIMENTAL; Interventions: Behavioral: Eye Movement Desensitization Reprocessing (EMDR) | Intervention Type: BEHAVIORAL; Name: Eye Movement Desensitization Reprocessing (EMDR); Assigned to Arm(s): Eye Movement Desensitization Reprocessing (EMDR)
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: TF-CBT | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Treatment as Usual (TAU) | Intervention Type: OTHER; Name: TF-CBT; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Treatment as Usual (TAU); Assigned to Arm(s): 2
C: Arm Label: Trauma Center Trauma-Sensitive Yoga (TCTSY); Type: EXPERIMENTAL; Interventions: Behavioral: Trauma Center Trauma Sensitive Yoga Intervention (TCTSY) | Arm Label: Cognitive Processing Therapy (CPT); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive Processing Therapy | Intervention Type: BEHAVIORAL; Name: Trauma Center Trauma Sensitive Yoga Intervention (TCTSY); Assigned to Arm(s): Trauma Center Trauma-Sensitive Yoga (TCTSY) | Intervention Type: BEHAVIORAL; Name: Cognitive Processing Therapy; Assigned to Arm(s): Cognitive Processing Therapy (CPT)
D: Arm Label: Control - VSLA; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Control - Mental Health; Type: OTHER; Interventions: Behavioral: Treatment as usual | Arm Label: Voluntary Savings/Loans Assoc; Type: EXPERIMENTAL; Interventions: Behavioral: Voluntary Savings/Loans Assoc | Arm Label: Cognitive Processing Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Processing Therapy | Intervention Type: BEHAVIORAL; Name: Treatment as usual; Assigned to Arm(s): Control - Mental Health | Intervention Type: BEHAVIORAL; Name: Voluntary Savings/Loans Assoc; Assigned to Arm(s): Voluntary Savings/Loans Assoc | Intervention Type: BEHAVIORAL; Name: Cognitive Processing Therapy; Assigned to Arm(s): Cognitive Processing Therapy

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Ziprasidone in the Treatment of Borderline Personality Disorder: A Double-Blind, Placebo-Controlled, Randomized Study
Brief Summary: Objective: The aim of this double-blind, placebo-controlled study was to evaluate the efficacy and tolerability of ziprasidone in the treatment of adult patients with Borderline Personality Disorder (BPD).

Method: Sixty BPD patients were included in a 12-week, single-center, double-blind, placebo-controlled study. The subjects were randomly assigned to ziprasidone or placebo in a 1:1 ratio following a two-week baseline period. The Clinical Global Impression scale for use in BPD patients (CGI-BPD) was the primary outcome measure, and other scales and self-reports related to affect, behavior, psychosis, general psychopathology domains and clinical safety were included.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lamotrigine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Lamotrigine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
B: Arm Label: Dialectical behavior therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Dialectical behavior therapy (DBT) | Arm Label: alternative psychotherapy; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Dialectical behavior therapy (DBT) | Intervention Type: BEHAVIORAL; Name: Dialectical behavior therapy (DBT); Assigned to Arm(s): Dialectical behavior therapy, alternative psychotherapy
C: Arm Label: Intervention (2Share) + treatment as usual; Type: EXPERIMENTAL; Interventions: Behavioral: 2Share | Arm Label: Treatment as usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: 2Share; Assigned to Arm(s): Intervention (2Share) + treatment as usual
D: Arm Label: I ziprasidone; Type: ACTIVE_COMPARATOR; Interventions: Drug: ziprasidone | Arm Label: II placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: ziprasidone; Assigned to Arm(s): I ziprasidone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): II placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Ziprasidone in the Treatment of Borderline Personality Disorder: A Double-Blind, Placebo-Controlled, Randomized Study
Brief Summary: Objective: The aim of this double-blind, placebo-controlled study was to evaluate the efficacy and tolerability of ziprasidone in the treatment of adult patients with Borderline Personality Disorder (BPD).

Method: Sixty BPD patients were included in a 12-week, single-center, double-blind, placebo-controlled study. The subjects were randomly assigned to ziprasidone or placebo in a 1:1 ratio following a two-week baseline period. The Clinical Global Impression scale for use in BPD patients (CGI-BPD) was the primary outcome measure, and other scales and self-reports related to affect, behavior, psychosis, general psychopathology domains and clinical safety were included.


Options:
A: Arm Label: Case management; Type: EXPERIMENTAL; Interventions: Behavioral: Case management | Arm Label: Enhanced usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: Enhanced usual care | Intervention Type: BEHAVIORAL; Name: Case management; Assigned to Arm(s): Case management | Intervention Type: OTHER; Name: Enhanced usual care; Assigned to Arm(s): Enhanced usual care
B: Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): N/A
C: Arm Label: I ziprasidone; Type: ACTIVE_COMPARATOR; Interventions: Drug: ziprasidone | Arm Label: II placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: ziprasidone; Assigned to Arm(s): I ziprasidone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): II placebo
D: Arm Label: Botulinum toxin A; Type: ACTIVE_COMPARATOR; Interventions: Drug: incobotulinumtoxin A | Arm Label: Acupuncture; Type: OTHER; Interventions: Procedure: Acupuncture | Intervention Type: DRUG; Name: incobotulinumtoxin A; Assigned to Arm(s): Botulinum toxin A | Intervention Type: PROCEDURE; Name: Acupuncture; Assigned to Arm(s): Acupuncture

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Adjuvant Immunotherapy With Anti-CTLA-4 Monoclonal Antibody (Ipilimumab) Versus Placebo After Complete Resection of High Risk Stage III Melanoma: A Randomized, Double-blind Phase 3 Trial of the EORTC Melanoma Group
Brief Summary: The purpose of the study is to determine if ipilimumab is effective in preventing or delaying recurrence and prolongs survival after complete resection of high risk stage III melanoma


Options:
A: Arm Label: Neoadjuvant treatment + Adjuvant treatment; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Arm Label: Adjuvant treatment; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab | Arm Label: Neo treat with patho response-driven Adju treat or observation; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Intervention Type: BIOLOGICAL; Name: Nivolumab; Assigned to Arm(s): Adjuvant treatment, Neo treat with patho response-driven Adju treat or observation, Neoadjuvant treatment + Adjuvant treatment | Intervention Type: BIOLOGICAL; Name: Ipilimumab; Assigned to Arm(s): Neo treat with patho response-driven Adju treat or observation, Neoadjuvant treatment + Adjuvant treatment
B: Arm Label: Imiquimod; Type: EXPERIMENTAL; Interventions: Drug: Imiquimod cream + surgery | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo + surgery | Intervention Type: DRUG; Name: Imiquimod cream + surgery; Assigned to Arm(s): Imiquimod | Intervention Type: DRUG; Name: Placebo + surgery; Assigned to Arm(s): Placebo
C: Arm Label: Nivolumab and CMP-001 Combination; Type: EXPERIMENTAL; Interventions: Drug: CMP-001, Biological: Nivolumab | Intervention Type: DRUG; Name: CMP-001; Assigned to Arm(s): Nivolumab and CMP-001 Combination | Intervention Type: BIOLOGICAL; Name: Nivolumab; Assigned to Arm(s): Nivolumab and CMP-001 Combination
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: ipilimumab | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: ipilimumab; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): B

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Positive Airway Pressure Initiation: Impact of Therapy Mode and Titration Process on Adherence and Outcomes
Brief Summary: Six month at home positive pressure therapy study; which mode of therapy will lead to better adherence and patient outcomes?


Options:
A: Arm Label: Standard Management; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Fast Track; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Fast Track | Intervention Type: PROCEDURE; Name: Fast Track; Assigned to Arm(s): Fast Track
B: Arm Label: Primary.; Type: EXPERIMENTAL; Interventions: Device: Diagnosis, autoCPAP, follow up. | Arm Label: Hospital; Type: ACTIVE_COMPARATOR; Interventions: Device: Diagnosis, autoCPAP, follow up. | Intervention Type: DEVICE; Name: Diagnosis, autoCPAP, follow up.; Assigned to Arm(s): Hospital, Primary.
C: Arm Label: Adherence to Sleep Apnea Treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Adherence to Sleep Apnea Treatment | Arm Label: Standard Care Group; Type: OTHER; Interventions: Other: Standard Care Group | Intervention Type: BEHAVIORAL; Name: Adherence to Sleep Apnea Treatment; Assigned to Arm(s): Adherence to Sleep Apnea Treatment | Intervention Type: OTHER; Name: Standard Care Group; Assigned to Arm(s): Standard Care Group
D: Arm Label: Auto Aflex; Type: ACTIVE_COMPARATOR; Interventions: Device: Auto AFlex | Arm Label: Auto CPAP; Type: ACTIVE_COMPARATOR; Interventions: Device: Auto CPAP | Arm Label: CPAP; Type: ACTIVE_COMPARATOR; Interventions: Device: CPAP | Intervention Type: DEVICE; Name: Auto AFlex; Assigned to Arm(s): Auto Aflex | Intervention Type: DEVICE; Name: Auto CPAP; Assigned to Arm(s): Auto CPAP | Intervention Type: DEVICE; Name: CPAP; Assigned to Arm(s): CPAP

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Positive Airway Pressure Initiation: Impact of Therapy Mode and Titration Process on Adherence and Outcomes
Brief Summary: Six month at home positive pressure therapy study; which mode of therapy will lead to better adherence and patient outcomes?


Options:
A: Arm Label: Auto Aflex; Type: ACTIVE_COMPARATOR; Interventions: Device: Auto AFlex | Arm Label: Auto CPAP; Type: ACTIVE_COMPARATOR; Interventions: Device: Auto CPAP | Arm Label: CPAP; Type: ACTIVE_COMPARATOR; Interventions: Device: CPAP | Intervention Type: DEVICE; Name: Auto AFlex; Assigned to Arm(s): Auto Aflex | Intervention Type: DEVICE; Name: Auto CPAP; Assigned to Arm(s): Auto CPAP | Intervention Type: DEVICE; Name: CPAP; Assigned to Arm(s): CPAP
B: Arm Label: Standard CPAP; Type: ACTIVE_COMPARATOR; Interventions: Device: Standard CPAP | Arm Label: CPAP - Flex; Type: ACTIVE_COMPARATOR; Interventions: Device: CPAP - Flex | Intervention Type: DEVICE; Name: Standard CPAP; Assigned to Arm(s): Standard CPAP | Intervention Type: DEVICE; Name: CPAP - Flex; Assigned to Arm(s): CPAP - Flex
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: Continuous Positive Airway Pressure (CPAP) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard care | Intervention Type: DEVICE; Name: Continuous Positive Airway Pressure (CPAP); Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Standard care; Assigned to Arm(s): 2
D: Arm Label: Fixed pressure; Type: ACTIVE_COMPARATOR; Interventions: Device: S8 Spirit 2, Device: Somnosmart 2, Device: Remstar Auto | Arm Label: Auto-adjusting pressure; Type: ACTIVE_COMPARATOR; Interventions: Device: S8 Spirit 2, Device: Somnosmart 2, Device: Remstar Auto | Intervention Type: DEVICE; Name: S8 Spirit 2; Assigned to Arm(s): Auto-adjusting pressure, Fixed pressure | Intervention Type: DEVICE; Name: Somnosmart 2; Assigned to Arm(s): Auto-adjusting pressure, Fixed pressure | Intervention Type: DEVICE; Name: Remstar Auto; Assigned to Arm(s): Auto-adjusting pressure, Fixed pressure

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Gabapentin Extended Release (G-ER) Tablets in the Treatment of Patients With Postherpetic Neuralgia
Brief Summary: Gabapentin and pregabalin are treatments for some types of neuropathic pain, including postherpetic neuralgia (PHN). However, these treatments usually need to be taken 3 times a day for effective pain control. The purpose of this study is to determine whether a new gabapentin tablet, which only needs to be taken once a day, is safe and effective for the treatment of postherpetic neuralgia.


Options:
A: Arm Label: G-ER; Type: EXPERIMENTAL; Interventions: Drug: Gabapentin Extended Release tablets | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Gabapentin Extended Release tablets; Assigned to Arm(s): G-ER | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Sham-laser acupuncture; Type: SHAM_COMPARATOR; Interventions: Device: Sham-laser acupuncture | Arm Label: gabapentine; Type: ACTIVE_COMPARATOR; Interventions: Drug: gabapentine | Arm Label: Acupuncture; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Acupuncture | Intervention Type: DEVICE; Name: Sham-laser acupuncture; Assigned to Arm(s): Sham-laser acupuncture | Intervention Type: DRUG; Name: gabapentine; Assigned to Arm(s): gabapentine | Intervention Type: PROCEDURE; Name: Acupuncture; Assigned to Arm(s): Acupuncture
C: Arm Label: Pregabalin; Type: ACTIVE_COMPARATOR; Interventions: Drug: pregabalin | Arm Label: Duloxetine; Type: EXPERIMENTAL; Interventions: Drug: duloxetine hydrochloride | Arm Label: Gabapentin + Duloxetine; Type: EXPERIMENTAL; Interventions: Drug: duloxetine hydrochloride, Drug: gabapentin | Intervention Type: DRUG; Name: duloxetine hydrochloride; Assigned to Arm(s): Duloxetine, Gabapentin + Duloxetine | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): Pregabalin | Intervention Type: DRUG; Name: gabapentin; Assigned to Arm(s): Gabapentin + Duloxetine
D: Arm Label: gabapentin; Type: EXPERIMENTAL; Interventions: Drug: gabapentin | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: gabapentin; Assigned to Arm(s): gabapentin | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): placebo

Answer: A